Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer-Reference-Cited by-同舟云学术

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Published:2022-10 Issue:10 Volume:102 Page:1101-1108
ISSN:0023-6837
Container-title:Laboratory Investigation
language:en
Short-container-title:Laboratory Investigation

Author:

Moutafi Myrto,Robbins Charles J.,Yaghoobi Vesal,Fernandez Aileen I.,Martinez-Morilla Sandra,Xirou Vasiliki,Bai Yalai,Song Yan,Gaule Patricia,Krueger Joseph,Bloom Kenneth,Hill Salisha,Liebler Daniel C.,Fulton Regan,Rimm David L.^ORCID

Funder

Breast Cancer Research Foundation

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Pathology and Forensic Medicine

Link

https://www.nature.com/articles/s41374-022-00804-9.pdf

Reference33 articles.

1. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018; 142: 1364–1382; e-pub ahead of print 2018/05/31; https://doi.org/10.5858/arpa.2018-0902-SA.

2. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–2671; https://doi.org/10.1200/JCO.1998.16.8.2659.

3. Howie LJ, Scher NS, Amiri-Kordestani L, Zhang L, King-Kallimanis BL, Choudhry Y, et al. FDA Approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2019; 25: 2949–2955; e-pub ahead of print 2018/12/16; https://doi.org/10.1158/1078-0432.Ccr-18-3003.

4. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008 13: 1114–1119; e-pub ahead of print 2008/10/14; https://doi.org/10.1634/theoncologist.2008-0816.

5. Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E, et al. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev 2017; 55: 16–25; https://doi.org/10.1016/j.ctrv.2017.01.001.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

2. Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer;npj Precision Oncology;2024-09-14

3. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay;Modern Pathology;2024-09

4. Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens;Diagnostic Cytopathology;2024-08-10

5. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15